Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-HFPEF tofogliflozin study in HFpEF with type 2 diabetes
jRCTs051210084Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tofogliflozin in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Change in E/e'. Started May 2022; status: recruiting.
02
Drugs
tofogliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051210084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210084.